Skip to content

Minerva Neurosciences, Inc.: 10-K filed 2020-03-09

What Minerva Neurosciences, Inc. reported in its annual report filed 2020-03-09 (fiscal FY 2019): 33 published measures, 81 facts as tagged in accession 0001564590-20-009243.

This filing

Form
10-K (annual report)
Filed
2020-03-09
Fiscal period
fiscal FY 2019
Accession
0001564590-20-009243 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Minerva Neurosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-12-3177,498,796USD
At 2018-12-31139,136,045USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-12-3149,719,253USD
At 2018-12-3148,871,276USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-12-3127,779,543USD
At 2018-12-3190,264,769USD
At 2017-12-31131,597,444USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-12-3121,412,623USD
At 2018-12-3150,234,871USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-10-01 to 2019-12-31-29,918,000USD92
2019-01-01 to 2019-12-31-72,183,490USD365
2019-07-01 to 2019-09-30-13,962,000USD92
2019-04-01 to 2019-06-30-12,476,000USD91
2019-01-01 to 2019-03-31-15,827,000USD90
2018-10-01 to 2018-12-31-13,203,000USD92
2018-01-01 to 2018-12-31-50,171,287USD365
2018-07-01 to 2018-09-30-12,021,000USD92
2018-04-01 to 2018-06-30-12,529,000USD91
2018-01-01 to 2018-03-31-12,418,000USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-43,432,223USD365
2018-01-01 to 2018-12-31-41,941,756USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-12-31524,999USD365
2018-01-01 to 2018-12-31-3,344,770USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-12-3114,084,976USD365
2018-01-01 to 2018-12-3169,489,576USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-12-31-286,736,218USD
At 2018-12-31-214,552,728USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-2,254,132USD365
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-31-9,400,000USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-12-3116,011USD
At 2018-12-3133,478USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-12-319,173,265USD365
2018-01-01 to 2018-12-318,182,678USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-10-01 to 2019-12-31-32,367,000USD92
2019-01-01 to 2019-12-31-75,865,096USD365
2019-07-01 to 2019-09-30-14,282,000USD92
2019-04-01 to 2019-06-30-12,904,000USD91
2019-01-01 to 2019-03-31-16,312,000USD90
2018-10-01 to 2018-12-31-13,627,000USD92
2018-01-01 to 2018-12-31-51,729,882USD365
2018-07-01 to 2018-09-30-12,424,000USD92
2018-04-01 to 2018-06-30-12,935,000USD91
2018-01-01 to 2018-03-31-12,744,000USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-12-3147,136,626USD
At 2018-12-3190,018,360USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-12-316,629,068USD
At 2018-12-313,609,198USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-12-312,317,004USD
At 2018-12-311,799,666USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2019-12-3114,869,399USD
At 2018-12-3114,869,399USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-01-01 to 2019-12-3175,865,096USD365
2018-01-01 to 2018-12-3151,729,882USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-12-3158,124,354USD365
2018-01-01 to 2018-12-3134,888,574USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-12-3139,084,121shares
At 2018-12-3138,937,971shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2019-12-3121,512,623USD
At 2018-12-3150,334,871USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2019-12-31261,952USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2019-12-3115,200,000USD
At 2018-12-3134,200,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-12-3114,808USD
At 2018-12-3114,808USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2018-12-3128,990USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2019-12-312,352,581USD
At 2018-12-315,290,728USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2019-12-311,803,356USD
At 2018-12-314,057,488USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-74,437,622USD365
2018-01-01 to 2018-12-31-50,171,287USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-72,183,490USD365
2018-01-01 to 2018-12-31-50,171,287USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-12-3117,740,742USD365
2018-01-01 to 2018-12-3116,841,308USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2019-01-01 to 2019-12-3117,467USD365
2018-01-01 to 2018-12-3117,467USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-01-01 to 2018-12-3192,916USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-31517,338USD365
2018-01-01 to 2018-12-31364,030USD365

Inspect the source

Entity
Minerva Neurosciences, Inc. / CIK 0001598646
Captured
2026-09-20T09:25:02.110Z
SEC response SHA-256
7b57da641574943cc8f7ca81f9c94ea1ff7a872915407c01165fb2137ec7efc4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001598646.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))